The embodiments provide a fluorescent rare earth complex having strong emission intensity and excellent durability, and also provide a security medium using the complex. The rare earth complex according to the embodiment comprises a rare earth ion, a diphosphine dioxide ligand and a β-diketone ligand wherein two phosphorus atoms contained in the diphosphine dioxide ligand individually have substituents different from each other.

The invention relates to a process for the preparation of dimeric contrast agents for use in Magnetic resonance Imaging (MRI), in particular [μ-[1-[bis[2-(hydroxy-kO)-3-[4,7,10-tris[(carboxy-kO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-kN.sup.1,kN.sup.4,kN.sup.7,kN.sup.10]propyl]amino]-1-deoxy-D-glucitolato(6-)]]di-gadolinium complex, which includes preparation steps carried out one-pot and without isolation of the obtained intermediate.

Optical tags provide a way to identify assets quickly and unambiguously, an application relevant to anti-counterfeiting and protection of valuable resources or information. The present invention is directed to a tag fluorophore that encodes multilayer complexity in a family of heterometallic rare-earth metal-organic frameworks (RE-MOFs) based on highly connected polynuclear clusters and carboxylic acid-based linkers. Both overt (visible) and covert (near infrared, NIR) properties with concomitant multi-emissive spectra and tunable luminescence lifetimes impart both intricacy and security. Tag authentication can be validated with a variety of orthogonal detection methodologies. The relationships between structure, composition, and optical properties of the family of RE-MOFs can be used to create a large library of rationally designed, highly complex, difficult to counterfeit optical tags.

The present invention relates to a complex of formula (II) constituted of at least 80% of a diastereoisomeric excess comprising a mixture of isomers II-RRR and II-SSS of formulae:

##STR00001##

The present invention also relates to a process for preparing said complex of formula (II), and also to two synthetic intermediates.

The present invention describes a compound of formula (I) which can be used in the diagnosis, treatment or prevention of neurotensin receptor-related conditions such as tumors and hematological malignancies. ##STR00001##

A hybrid separator for an electrochemical cell is provided, along with methods of making the hybrid separator. The hybrid separator includes a first metal-organic framework comprising copper and having a plurality of first pores and a second distinct metal-organic framework comprising indium or zinc and having a plurality of second pores. The hybrid separator is capable of adsorbing one or more lithium salts in at least one of the plurality of first pores or the plurality of second pores so as to be ionically conductive. The hybrid separator may have a conductivity greater than or equal to about 0.1 mS/cm to less than or equal to about 1 mS/cm and is substantially free of any polymeric binder.

Compounds based on an element from Groupe IIIA (column 13) of the periodic table of the elements, such as boron, aluminum, gallium or indium, are here described, as well as their processes of preparation and their use as salts and/or additives, for instance, in combination with other salts in electrolyte compositions for electrochemical cells, inter alia, in electrolyte compositions in the presence of a liquid solvent and/or a solvating polymer, the electrolyte being in liquid, gel or solid form.

The present invention provides a method for preparing a cyclic carbonate, which has the advantages of high yield, mild reaction conditions, high catalytic efficiency under room temperature and 1 atm pressure conditions, and wide substrate scopes. It is not only suitable for monosubstituted epoxides, but also suitable for disubstituted epoxides. The method comprises the step of reacting epoxides of Formula (I) with carbon dioxide in the presence of a quaternary ammonium salt and a catalyst, to obtain a cyclic carbonate of Formula (II). The reaction formula is:

##STR00001##

An MRI contrast composition includes a liposome and a europium metal complex disposed within the liposome. The europium metal complex includes a europium metal ion and a multi-dentate ligand selected from the group consisting of cryptands and thiacryptands and one or more counter-ions that balances a charge of the europium metal ion and the multi-dentate ligand, the europium metal ion being switchable between a 2÷ and 3÷ oxidation state. The contrast composition advantageously provides an oxidation-responsive dual-mode contrast agent because it would enhance either T.sub.1-weighted images or CEST images depending on the oxidation state of Eu.

Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA.

##STR00001##